Purpose: This study aims to investigate the serum adiponectin, interleukin (IL)-6 and oxidative stress in epilepsy patients who are refractory or non-refractory to treatments. Method: The study comprised 31 refractory epilepsy, 29 well-controlled epilepsy patients and control group including 29 healthy individuals. The serum adiponectin, IL-6, total antioxidant status (TAS), total oxidant status levels (TOS) and oxidative stress index (OSİ) were determined. Results: The mean serum adiponectin and TAS levels were significantly lower in the refractory epilepsy patients than in the healty controls, and mean IL-6, TOS and OSİ levels were significantly higher. The serum adiponectin, IL-6, TAS, TOS and OSI levels were not significantly different between the well-controlled epilepsy patients and the healthy controls. Conclusions: The mean serum IL-6 and oxidative stress levels in refractory epilepsy patients were higher and the serum adiponectin level was lower than the healthy control group. These findings may be associated with an increased risk of seizures, atherosclerosis and cardiovascular disease in refractory epilepsy patients.
Introduction
Inflammation and oxidative stress play important roles in the pathogenesis of neurodegenerative disease [1, 2] . In recent experimental and clinical studies, it has been indicated that inflammation and oxidative stress can influence the beginning of an epileptic seizure as well as seizure recurrence [3, 4] .
Sudden unexpected death in epilepsy (SUDEP), especially in epilepsy refractory to treatment, is the leading cause of death in these patients [5] . It has been shown that a cardiac disorder, especially an arrhythmia, is the major etiological cause of SUDEP [6] . It is also known that inflammation and oxidative stress play affective roles in the pathogenesis of cardiovascular disease [7] .
Adipocytokines, such as adiponectin and interleukin (IL)-6, which are secreted from adipose tissue, play roles in inflammation [8] . Adiponectin has anti-inflammatory, anti-atherosclerotic and anti-oxidative characteristics, and its level decreases in increased oxidative stress environments [9] . It has been reported that a lower serum adiponectin level is related to hypertension, dyslipidemia and inflammation [10] . In one mouse study by Lee et al., it was determined that there was a relationship between the lack of adiponectin and an increased lipid level and the seizure severity [11] .
It is well-known that IL-6 increases in response to chronic inflammation [12] . In studies carried out previously, it was reported that in inflammatory system activation in refractory epilepsy there is a relationship between recurrent seizures in chronic epilepsy patients and the overproduction of IL-6 [13] [14] [15] . In mice, it has been shown that the chronic overproduction of IL-6 can cause seizures and neurodegeneration [16] . Additionally, another mouse study carried out by Kalueff et al. revealed that there is an increase in seizure severity triggered chemically when mice receive intranasal IL-6. This showed that IL-6 plays an important proconvulsive role [17] . After a seizure, the level of IL-6 increases not only in the brain but also in the periphery [18] .
In accordance with our data, there have been no studies determining the relationships between the serum adiponectin, IL-6 and oxidative stress in epilepsy patients. In light of this information, our aim was to investigate these three factors in both refractory and non-refractory epilepsy patients.
Medicine Hospital in the Neurology and Clinical Biochemistry Department (Turkey). The study group consisted of 31 refractory epilepsy patients, 28 controlled epilepsy patients and a control group including 29 healthy individuals. Ethics committee approval was obtained from the Harran University Department of Medicine before this study began. Our study was planned in accordance with the criteria established in the Declaration of Helsinki. Informed consent forms were received from both the epilepsy patients participating in this study and the healthy controls.
All the patients were diagnosed with epilepsy by evaluating the clinical symptomology, electroencephalography and magnetic resonance imaging findings. The well-controlled epilepsy group consisted of those patients who had no seizures over the last 1 year. The refractory epilepsy group consisted of those patients in which seizure control could not be achieved, even if two tolerable antiepileptic medicines were used together (or separately) with appropriate dosages and time periods [19] .
A detailed medical history of each patient, including the age, gender, weight (kg), length (cm), body mass index (BMI) (kg/m 2 ), disease period, annual seizure frequency, seizure type, antiepileptic medicine usage and epileptic seizure control status, was recorded. The epileptic patient exclusion criteria were as follows: usage of drugs other than antiepileptic medications, chronic systemic disease, presence of hyperlipidemia and having a seizure within the last 24 h. The healthy control group consisted of individuals of the same ages, genders and BMIs, without diseases and medication usage histories. The physical and neurological examinations of the healthy controls were normal.
Biochemical analysis
All the biochemistry measurements were performed at the Harran University, Department of Medicine Hospital in the Clinical Biochemistry Laboratory. Following 12-h fasting, 100 cc of venous blood was collected, and it was stored at −80°C after centrifugation at 5000 rpm for 10 min. The total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels of the serum were measured using a spectrophotometric analyser (Architect c16000 analyser; Abbott Diagnostics, Abbott Park, IL, USA). The total antioxidant status (TAS) level was measured via the spectrophotometric method using the appropriate assay kit (Rel Assay Diagnostics, Sehitkamil, Gaziantep, Turkey) developed by Erel [20] (Thermo Scientific Multiskan GO; Thermo Fisher Scientific, Vantaa, Finland). Trolox (Hoffman-LaRoche, Basel, Switzerland), which is a water-soluble analogue of vitamin E, was used as a calibrator, and the results were represented in mmol Trolox equivalents/litre. The total oxidant status (TOS) level was measured via the spectrophotometric method by using the appropriate assay kit (Rel Assay Diagnostics) developed by Erel [21] (Thermo Scientific Multiskan GO; Thermo Fisher Scientific). Hydrogen peroxide was used as a calibrator, and the results were expressed in μmol H 2 O 2 equivalents/litre. The oxidative stress index (OSI) was represented as the TOS/TAS percentage rate, and the mmol value in the TAS test unit was converted into a μmol unit, as in the TOS test [21] . The results were represented as "arbitrary units" (AU) and calculated according to the formula provided below:
The serum adiponectin was measured in all the patients and healthy controls using an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Elabscience Biotechnology Co.,Ltd, Wuhan, China). In addition, the serum IL-6 was assessed using an ELISA kit (Thermo Fisher Scientific, Waltham, MA, USA).
Statistical analyses
The statistical analysis was conducted using the Statistical Package for the Social Sciences for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA) software program. The metadata were represented with averages ± standard deviations, numbers and percentages. Categorical variables were compared using chi-square test. In the normally distributed constant data comparison, the Student's t-test was used, and in the non-normally distributed group, the Mann-Whitney U test was used. The Kruskal-Wallis test was used to compare more than two independent groups. A P < 0.05 value was accepted as the significance level.
Results
This study included a total of 59 epilepsy patients (mean age 28.15 ± 9.92 years old), including 31 refractory patients (mean age 29.32 ± 10.5 years old) and 28 well-controlled patients (mean age 26.85 ± 9.24years old), and 29 healthy controls (mean age 25.17 ± 7.07years old). There were no significant differences between the resistant epilepsy group, well-controlled epilepsy group and control group in terms of the age, sex and BMI. The clinical findings of the control and epilepsy groups are shown in Table 1 .
It was found that the mean serum TAS and adiponectin levels were significantly lower and the mean serum IL-6, TOS and OSI levels were significantly higher in the refractory epilepsy patients when they were compared to the healthy controls. The serum adiponectin was significantly lower and the mean serum IL-6 and OSI levels were significantly higher in the refractory patients when they were compared to the well-controlled epilepsy. There were no significant differences in terms of the mean serum adiponectin, IL-6, TAS, TOS and OSI levels between the well-controlled epilepsy and the healthy control group (Table 2, Fig. 1) .
The mean serum LDL-C and cholesterol levels were higher in the refractory epilepsy patients when compared to the healthy control group. There were no significant differences between the refractory epilepsy group and the well-controlled group nor between the wellcontrolled group and the healthy controls with respect to the serum LDL-C, TC, TG and HDL-C levels ( Table 2) .
When we compared the patients with epilepsy who received polytherapy with those who received monotherapy, the mean serum IL-6, TOS and OSI levels were significantly higher, and mean serum adiponectin value was significantly lower in the epilepsy group receiving polytherapy. However, there were no significant differences in terms of the mean serum LDL-C, TC, TG and HDL-C (Table 3 ).
Discussion
Epilepsy is a disease that affects 50 million people worldwide, and of these patients, almost 30-40% are refractory to therapy [22] . Sudden unexpected death is an issue experienced in epilepsy patients at a rate of 16-36%, especially in refractory epilepsy patients, in which it is the leading cause of death [5] . Many studies have reported that autonomic and cardiac function disorders can be related to the modulation of the SUDEP risk. Moreover, it is already known that chronic inflammation and oxidative stress play roles in the pathophysiology of cardiovascular disease and epilepsy [23, 24] .
In addition to the fact that oxidation plays an important role in the pathogenesis of epilepsy, recurrent and prolonged seizures can cause oxidative stress and the formation of free radicals, resulting in lipid, protein and DNA damage, inflammation and neurotoxicity [25, 26] . There have also been studies indicating that the higher oxidative stress levels (lipid peroxidation, nitric oxide, protein carbonyls) and the lower antioxidants markers (paraxonase, superoxide dismutase, glutathione, glutathione peroxidase, catalase, thiol, vitamin E) in epilepsy patients when compared with healthy individuals [27] [28] [29] [30] . Recently, it has been reported that antioxidant treatment reduces the mortality rate in status epilepticus, and it has a neuroprotective effect against the neuronal damage triggered by status epilepticus [31] . Similarly, studies carried out with mice have revealed that the addition of antioxidant treatment to antiepileptic treatment (AET) reduces the severity and frequency of seizures [32, 33] . In our study, the serum TOS and OSI values were significantly higher, and the serum TAS value was significantly lower in the refractory epilepsy group than in the healthy control group.
Blood concentrations of cytokines such as IL-1β, IL-6, and TNF-α have been shown to be increased in rats with chronic seizures induced by pilocarpine [34] . A recent study of adult epilepsy patients demonstrated that proinflammatory cytokines including IL-1β, IL-2, IL-6, IL-17, IFN-γ, and TNF-α, anti-inflammatory cytokines including IL-4 and TGF-β were not significantly different between the epilepsy patients and healthy individuals [35] . This result may be due to the fact that patients who have not had seizures for at least 6 months have been taken to this study. In addition, there were no significant differences in terms of the mean serum adiponectin, IL-6, TAS, TOS and OSI levels between the well-controlled epilepsy and the healthy control group in our study.
Nejim et al. reported that in the hearts of mice with refractory epilepsy, the IL-6 levels were high. IL-6 increased the seizure recurrence in the brain, heart and plasma, and it could lead to SUDEP by causing the development of cardiac anomalies [36] . In another experimental study, it was reported that IL-6 increased the seizure severity and mortality rate after intranasal administration, and this may have been Interleukin 6:IL-6, total antioxidant status: TAS, total oxidant status: TOS, oxidative stress index: OSI, TC: total cholesterol, TG: triglyceride, HDL-C: highdensity lipoprotein-cholesterol, LDL-C: low-densitylipoprotein-cholesterol, values are mean ± SD, P : within groups, P1: significance between refractory and well-controlled, P2: significance between well controlled-control, P3, significance between refractory-control. Fig. 1 . Mean serum adinopectin, IL-6, TAS, TOS and OSI levels in the epilepsy patients and control group.
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due to its proconvulsive effect [37] . However, Hulkkonen et al. found that the IL-6 was elevated in patients with treatment-resistant epilepsy [38] ; therefore, it can cause the development of refractory seizures by creating structural changes in the neural tissue [39] . In line with the above-mentioned studies, in our study, the serum IL-6 levels were found to be significantly higher in the patients with resistant epilepsy when compared to the healthy control group. Adiponectin has anti-inflammatory, anti-atherosclerotic and vascular-protective effects (9) . It is known that adiponectin has a reducing effect on proinflammatory cytokines, such as IL-6 and tumour necrosis factor (TNF)-α, via the regulation of inflammatory pathways. It also has a preventive effect on ischemic brain damage [40, 41] . In a study carried out with mice, Tang et al. indicated that there was a decrease in the adiponectin in an increased oxidative stress environment [9] . Additionally, Jeon et al. determined that in mice with seizures triggered by kainic acid, the oxidative stress was increased and the adiponectin was decreased. After an intracerebral ventricular injection of adiponectin, there was a decrease in the excitotoxicity triggered by the kainic acid [42] . In our study, the serum adiponectin levels were significantly lower in the patients with refractory epilepsy than in the healthy control group.
When epilepsy patients not receiving AET and epilepsy patients receiving AET were compared, the patients not receiving AET exhibited significantly higher oxidative stress symptoms when compared with the healthy controls [43] . However, in another study, epilepsy patients receiving AET and epilepsy patients not receiving AET were compared, and there was no significant difference in terms of the antioxidant status [44] . This shows that there is no AET effect on the oxidative stress symptoms. In our study, the TOS, OSI and IL-6 levels were significantly higher in the patients receiving polytherapy when compared to the patients receiving monotherapy, while the TAS and adiponectin levels were significantly lower. We believe that this finding is due to the fact that the patients receiving monotherapy consisted of controlled epilepsy patients, as well as the recurrent seizure frequency in the patients receiving polytherapy.
Hyperlipidaemia is one of the principal comorbidities seen in epilepsy patients [45] . It has been shown that there is a significant relationship between chronic epilepsy, antiepileptic medicine usage and atherosclerosis [46] . Moreover, the association between dyslipidaemia and cardiovascular disease is well known [47] . In epilepsy patients, the rate of deaths due to cardiovascular diseases is 1.5-2.5 higher than that in the normal population [48] . In our study, we determined that the LDL-C and TC levels were significantly higher in the refractory epilepsy group when compared with the healthy control group, but there was no significant relationship between the refractory epilepsy group and the well-controlled group. The limitations of our study included the small sample size.
In conclusion, the results of this study showed that in refractory epilepsy patients, the serum LDL-C, TC, IL-6 and oxidative stress levels were higher and the serum adiponectin level was lower than in the healthy control group. These findings may be associated with an increased risk of seizures, atherosclerosis and cardiovascular disease in refractory epilepsy patients. Therefore, the current study indicates that an increased inflammatory response and the oxidative status can affect a patient's prognosis and cause cardiovascular problems. In epilepsy patients in whom antiepileptic therapy has failed, new therapy targets should be developed to regulate the inflammatory response and oxidative stress by considering the ADP, IL-6 and oxidative system.
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